Johnson & Johnson the U.S. FDA Oncologic Drugs Advisory Committee voted (6-2) in favor of the benefit-risk profile of single-agent Darzalex Faspro for the treatment of adult patients with high-risk smoldering multiple myeloma. An application for the approval of Darzalex Faspro for adult patients with HR-SMM was submitted to the FDA in November 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- HHS says ‘taking immediate steps to implement’ Trump drug pricing order
- CMS demands on drug pricing ‘extreme,’ ‘highly problematic,’ says Leerink
- Sector Spotlight: Trump executive order targets drug prices
- Janssen-Cilag’s Tremfya approved by U.K.’s MHRA for Crohn’s disease, UC
- Unusually active option classes on open May 15th